2018 News | University of Maryland School of Medicine

May 11, 2018

Robert Edelman, MD

Physician, investigator, scholar, leader, and mentor

Dr. Robert Edelman’s legacy will live long past his tenure at the Center for Vaccine Development and Global Health (CVD). Prior to an esteemed career in academia, he served in the military and the US public health service. Dr. Edelman’s work includes vaccines against dengue, malaria, hepatitis, enteric infections, and Lyme disease. He is an expert on bioethics of clinical trials, co-chaired the Institutional Review Board at UMSOM, and directed the Clinical Research Training and Mentoring Program. In his free time, founded the Traveler Medicine Practice, formerly the Travel Clinic.

Anyone that knows Dr. Edelman is used to his bright smile, engaging stories, and incredible breadth and depth of knowledge. He will be deeply missed and fondly remembered by all those that had the honor of working with him at the CVD.

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.

Friday, February 05, 2021

UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests

Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.

Tuesday, February 25, 2020

World Health Organization Names UMSOM Faculty Member as COVID-19 Advisor

Samba Sow, MD, MSc, FASTMH, Director General of the Center for Vaccine Development in Mali (CVD-Mali), and Adjunct Professor of Medicine at the University of Maryland School of Medicine (UMSOM), was appointed by the World Health Organization (WHO) to serve as a special envoy on issues related to coronavirus COVID-19.

Tuesday, December 10, 2019

UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water

Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.

Friday, September 20, 2019

UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research

Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.

Tuesday, August 13, 2019

UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases

Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world’s most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases.

Friday, November 02, 2018

UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel

Wednesday, June 06, 2018

UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease

In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.

Tuesday, May 15, 2018

Tackling Malaria Transmission in Sub-Saharan Africa

Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.

Thursday, May 03, 2018

Low Efficacy Influenza Vaccines Can Still Significantly Avert Infections, Study Shows

Research published in PNAS, showed that even less effective influenza vaccines can still help to reduce illnesses, hospitalizations and other issues as long as the vaccine is broadly administered across age groups.

Honoring Dr. Robert Edelman for Three Decades of Service at UMSOM